种族与时间的关联导致严重的肝病诊断
Andrew D Schreiner1, Jingwen Zhang1, Mulugeta Gebregziabher2
1Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
PloS one
|October 14, 2025
概括
在初级保健患者中,黑人种族与严重肝病诊断的时间更长有关. 这表明肝硬化检测或肝纤维化进展的潜在种族差异.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床研究 临床研究
- 健康差异 在健康上的差异
背景情况:
- 记录了慢性肝病 (CLD) 患者肝纤维化进展的种族差异.
- 这项研究调查了黑人种族与严重肝病诊断的时间之间的联系.
研究的目的:
- 检查黑人种族与诊断严重肝病结果的时间之间的关联.
- 探索肝病进展和诊断中的潜在种族差异.
主要方法:
- 利用来自一家初级保健诊所 (2012-2021) 的电子健康记录数据.
- 种族分类为黑人和非黑人,主要结果是严重的肝病 (肝硬化,并发症,肝细胞癌,肝移植).
- 采用考克斯回归模型来评估关联,调整共变量.
主要成果:
- 该队列包括20828名患者;43%的人被确定为黑人,14%的人被诊断为CLD.
- 严重的肝脏事件发生在所有患者的3%.
- 调整后的考克斯回归显示,黑人种族与严重肝脏结果的风险明显较低相关 (HR 0.68;95%CI 0.57-0.81).
结论:
- 黑人种族在调整混因素后,与严重肝病诊断的时间更长有关.
- 研究结果表明,在种族群体之间,肝硬化检测或肝纤维化进展的变化可能会延迟.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
212
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
212
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
253
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
253
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
212
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
212


